FT-671

  Cat. No.:  DC11554  
FT-671
Chemical Structure
1959551-26-8
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
FT-671 is a novel potent, specific, non-covalent USP7 inhibitor with Kd of 65 nM (USP7 catalytic domain).
Cas No.: 1959551-26-8
Chemical Name: (S)-5-((1-(4,4-difluoro-3-(3-fluoro-1H-pyrazol-1-yl)butanoyl)-4-hydroxypiperidin-4-yl)methyl)-1-(4-fluorophenyl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one
Synonyms: FT671;FT 671
SMILES: C1N(CC(O)2CCN(C(=O)C[C@@H](N3C=CC(F)=N3)C(F)F)CC2)C(=O)C2C=NN(C3=CC=C(F)C=C3)C=2N=1
Formula: C24H23F4N7O3
M.Wt: 533.488
Purity: >98%
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Publication:
Description: FT-671 is a novel potent, specific, non-covalent USP7 inhibitor with Kd of 65 nM (USP7 catalytic domain); inhibits USP7 with IC50 values of 52 nM (USP7 CD) and 69 nM (USP7C-term), display good USP7 selectivity in a panel of 38 deubiquitinases (DUBs); destabilizes USP7 substrates including MDM2, increases levels of p53, and results in the transcription of p53 target genes and induces tumour suppressor p21; blocks the proliferation of MM.1S cells (IC50=33 nM), suppresses tumour growth in mice; orally available.
In Vivo:
In Vitro:
References:
Kinase Assay:
Cell Assay:
Animal Administration:
References:
MSDS
COA
LOT NO. DOWNLOAD
2018-0101
Cat. No. Product name Field of application
DC28734 6RK73 6RK73 is a covalent irreversible and specific UCHL1 inhibitor with an IC50 of 0.23 µM. 6RK73 shows almost no inhibition of UCHL3 (IC50=236 µM). 6RK73 specifically inhibit UCHL1 activity in breast cancer.
DC28552 USP7-IN-6 USP7-IN-6 is a potent ubiquitin specific protease 7 (USP7) inhibitor, extracted from patent WO2017212010A1, example 25, has an IC50 of 6.8 nM.
DC28551 USP7-IN-5 USP7-IN-5 is a potent ubiquitin specific protease 7 (USP7) inhibitor extracted from patent WO2017212012A1, example 40, has an IC50 of 49.9 nM.
DC11876 XL 188 XL188 (XL-188) is a potent, selective, non-covalent active-site inhibitor of USP7 with IC50 of 90 nM and 193 nM for USP7 full length enzyme and catalytic domain, respectively.
DC7525 USP7-USP47 inhibitor USP7/USP47 inhibitor is a potent and dual inhibitor of USP7/USP47 with IC50s of 0.42 uM(USP7) and 1.0 uM(USP47).
DC11509 USP25 and 28 inhibitor AZ-2 USP25 and 28 inhibitor AZ-2 is a potent, selective, dual USP25/28 inhibitor with IC50 of 0.9/0.9 uM, respectively.
DC10298 Ubiquitin Isopeptidase Inhibitor I, G5 Ubiquitin Isopeptidase Inhibitor I, G5 (NSC 144303) is an apoptosome-independent caspase and apoptosis activator with IC50 values of 1.76 and 1.6 μM in E1A and E1A/C9DN cells, respectively.
DC10917 MF-094 MF-094 (MF094) is a potent, highly selective inhibitor of ubiquitin specific protease 30 (USP30) with IC50 of 0.12 uM, demonstrates <30% inhibitory activity for a panel of 22 USPs assays at 10 uM.
DC7610 LDN-57444 LDN-57444 is a reversible, competitive proteasome inhibitor for Uch-L1 with IC50 of 0.88 μM, 28-fold selectivity over isoform Uch-L3.
DC10354 HBX 19818 HBX 19818 is a selective USP7 inhibitor with IC50 of 28.1 uM .